The anti-microbial peptide SR-0379 stimulates human endothelial progenitor cell-mediated repair of peripheral artery diseases
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Ischemia is a serious disease, characterized by an inadequate blood supply to an organ or part of the body. In the present study, we evaluated the effects of the anti-microbial peptide SR-0379 on the stem cell-mediated therapy of ischemic diseases. The migratory and tube-forming abilities of human endothelial progenitor cells (EPCs) were enhanced by treatment with SR-0379 in vitro. Intramuscular administration of SR-0379 into a murine ischemic hindlimb significantly enhanced blood perfusion, decreased tissue necrosis, and increased the number of blood vessels in the ischemic muscle. Moreover, co-administration of SR-0379 with EPCs stimulated blood perfusion in an ischemic hindlimb more than intramuscular injection with either SR-0379 or EPCs alone. This enhanced blood perfusion was accompanied by a significant increase in the number of CD31- and -SMApositive blood vessels in ischemic hindlimb. These results suggest that SR-0379 is a potential drug candidate for potentiating EPC-mediated therapy of ischemic diseases.
Abstract
Ischemia is a serious disease, characterized by an inadequate blood supply to an organ or part of the body. In the present study, we evaluated the effects of the anti-microbial peptide SR-0379 on the stem cell-mediated therapy of ischemic diseases. The migratory and tube-forming abilities of human endothelial progenitor cells (EPCs) were enhanced by treatment with SR-0379 in vitro. Intramuscular administration of SR-0379 into a murine ischemic hindlimb significantly enhanced blood perfusion, decreased tissue necrosis, and increased the number of blood vessels in the ischemic muscle. Moreover, co-administration of SR-0379 with EPCs stimulated blood perfusion in an ischemic hindlimb more than intramuscular injection with either SR-0379 or EPCs alone. This enhanced blood perfusion was accompanied by a significant increase in the number of CD31- and -SMApositive blood vessels in ischemic hindlimb. These results suggest that SR-0379 is a potential drug candidate for potentiating EPC-mediated therapy of ischemic diseases.
참고문헌 (26)
- Brevetti G, "Inflammation in peripheral artery disease", Circulation, 122, pp.1862~1875 (2010)
- Hirsch AT, "The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease", Vasc Med, 2, pp.243~251 (1997)
- Jude EB, "Peripheral arterial disease in diabetic and nondiabetic", Diabetes Care, 24, pp.1433~1437 (2001)
- Belch JJ, "Critical issues in peripheral arterial disease detection and management: a call to action", Arch Intern Med, 163, pp.884~892 (2003)
- Youssef F, "Risk modification in patients with peripheral arterial disease: a retrospective survey", Angiology, 56, pp.279~287 (2005)
- Annex BH, "Therapeutic angiogenesis for critical limb ischaemia", Nat Rev Cardiol, 10, pp.387~396 (2013)
- Duan J, "Hypercholesterolemia inhibits angiogenesis in response to hindlimb", Circulation, 102, pp.Iii370~Iii376 (2000)
- Duan J, "Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia", Arterioscler Thromb Vasc Biol, 20, pp.2579~2585 (2000)
- Cheng XW, "Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase", Akt-dependent hypoxiainduced factor-1 alpha reactivation in mice of advanced age, 2010, pp.122, 707~716
- Djonov V, "Vascular remodeling by intussusceptive angiogenesis", Cell Tissue Res, 314, pp.107~117 (2003)
- Patan S, "Vasculogenesis and angiogenesis", Cancer Treat Res, 117, pp.3~32 (2004)
- Reyes M, "Origin of endothelial progenitors in human postnatal bone marrow", J Clin Invest, 109, pp.337~346 (2002)
- Hristov M, "Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance", J Cell Mol Med, 8, pp.498~508 (2004)
- Urbich C, "Endothelial progenitor cells: characterization and role in vascular biology", Circ Res, 95, pp.343~353 (2004)
- Rouhl RP, "Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts", Stroke, 39, pp.2158~2165 (2008)
- Zampetaki A, "Vascular repair by endothelial progenitor cells", Cardiovasc Res, 78, pp.413~421 (2008)
- Krenning G, "Endothelial progenitor cell-based neovascularization: implications for therapy", Trends Mol Med, 15, pp.180~189 (2009)
- Asahara T, "VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells", Embo j, 18, pp.3964~3972 (1999)
- Xu S, "Endothelial progenitor cells: current development of their paracrine factors in cardiovascular therapy", J Cardiovasc Pharmacol, 59, pp.387~396 (2012)
- Tomioka H, "Novel anti-microbial peptide SR-0379 accelerates wound healing via the PI3 kinase", Akt, PLoS One, pp.2014, 9[DOI]
- Nishikawa T, "Development of a novel antimicrobial peptide, AG-30, with angiogenic properties", J Cell Mol Med, 13, pp.535~546 (2009)
- Nakagami H, "Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents", J Cell Mol Med, 16, pp.1629~1639 (2012)
- Smith LE, "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor", Nat Med, 5, pp.1390~1395 (1999)
- Rabinovsky ED, "Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis", Mol Ther, 9, pp.46~55 (2004)
- Fan W, "Adipose stromal cells amplify angiogenic signaling via the VEGF", mTOR, PLoS One, pp.2012, 7[DOI]
- Woo KY, "A randomized controlled trial to evaluate an antimicrobial dressing with silver alginate powder for the management of chronic wounds exhibiting signs of critical colonization", Adv Skin Wound Care, 25, pp.503~508 (2012)